Phase 2 Randomized Trial of an AS03 Adjuvanted Plant-Based Virus-Like Particle Vaccine for Covid-19 in Healthy Adults, Older Adults and Adults with Comorbidities
Data Availability
Medicago Inc. is committed to providing access to anonymized data collected during the trial that underlie the results reported in this article, at the end of the clinical trial, which is currently scheduled to be 1 year after the last participant is enrolled, unless granted an extension. Medicago Inc. will collaborate with its partners (GlaxoSmithKline, Belgium) on such requests before disclosure. Proposals should be directed to wardb@medicago.com or daoustma@medicago.com. To gain access, data requestors will need to sign a data access agreement and access will be granted for non-commercial research purposes only. The following publicly-available databases were accessed to complete this work: GISAID database (https://www.gisaid.org/) and Genbank (https://www.ncbi.nlm.nih.gov/genbank/).
Subject Area
- Addiction Medicine (399)
- Allergy and Immunology (708)
- Anesthesia (200)
- Cardiovascular Medicine (2918)
- Dermatology (249)
- Emergency Medicine (438)
- Epidemiology (12711)
- Forensic Medicine (12)
- Gastroenterology (827)
- Genetic and Genomic Medicine (4567)
- Geriatric Medicine (415)
- Health Economics (726)
- Health Informatics (2913)
- Health Policy (1068)
- Hematology (386)
- HIV/AIDS (922)
- Medical Education (422)
- Medical Ethics (115)
- Nephrology (467)
- Neurology (4335)
- Nursing (234)
- Nutrition (636)
- Oncology (2261)
- Ophthalmology (643)
- Orthopedics (258)
- Otolaryngology (324)
- Pain Medicine (278)
- Palliative Medicine (83)
- Pathology (499)
- Pediatrics (1196)
- Primary Care Research (494)
- Public and Global Health (6916)
- Radiology and Imaging (1524)
- Respiratory Medicine (915)
- Rheumatology (436)
- Sports Medicine (383)
- Surgery (486)
- Toxicology (60)
- Transplantation (210)
- Urology (178)